Literature DB >> 11967493

Defective regulation of the proinflammatory immune response in women with vulvar vestibulitis syndrome.

Stefan Gerber1, Ann Marie Bongiovanni, William J Ledger, Steven S Witkin.   

Abstract

OBJECTIVE: The cause of vulvar vestibulitis syndrome is unknown. To determine a possible role for defective immune regulation in this chronic condition, proinflammatory and anti-inflammatory immune responses to the 70-kd heat shock protein and to lipopolysaccharide were compared in women with and without vulvar vestibulitis syndrome. STUDY
DESIGN: Whole blood cultures from 62 women with vulvar vestibulitis syndrome and 48 control subjects were incubated in the presence or absence of 5 microg/mL human recombinant 70-kd heat shock protein or 0.1 ng/mL lipopolysaccharide for 18 hours. The culture supernatants were then assayed for interleukin-1 beta and interleukin-1 receptor antagonist by enzyme-linked immunosorbent assay.
RESULTS: Median levels of interleukin-1 beta were higher in response to heat shock protein in cultures from patients with vulvar vestibulitis syndrome (median, 1.07 ng/mL) as opposed to control subjects (median, 0.40 ng/mL; P =.006). Conversely, levels of interleukin-1 receptor antagonist were higher in response to heat shock protein in control subjects (median, 39.21 ng/mL) than in patients (median, 29.25 ng/mL; P =.009). In response to lipopolysaccharide, median levels of interleukin-1 beta were similar in patients (1.00 ng/mL) and control subjects (1.15 ng/mL); median interleukin-1 receptor antagonist concentrations were higher in control subjects (70.0 ng/mL) than in patients (44.3 ng/mL; P <.0001). The ratio of interleukin-1 receptor antagonist to interleukin-1 beta was higher in control subjects than in women with vulvar vestibulitis syndrome in response to both heat shock protein (P =.0002) and lipopolysaccharide (P =.01). In uninduced cultures, interleukin-1 receptor antagonist levels were also higher in control subjects (median, 1.60 ng/mL) than in patients with vulvar vestibulitis syndrome (median, 0.62 ng/mL; P <.0001).
CONCLUSION: A relative inability to down-regulate proinflammatory interleukin-1 beta activity by interleukin-1 receptor antagonist may contribute to the pathophysiologic features of vulvar vestibulitis syndrome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11967493     DOI: 10.1067/mob.2002.121869

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  9 in total

1.  Differences in primary compared with secondary vestibulodynia by immunohistochemistry.

Authors:  Catherine M Leclair; Martha F Goetsch; Veselina B Korcheva; Ross Anderson; Dawn Peters; Terry K Morgan
Journal:  Obstet Gynecol       Date:  2011-06       Impact factor: 7.661

Review 2.  [Vulvodynia].

Authors:  U R Hengge; I B Runnebaum
Journal:  Hautarzt       Date:  2005-06       Impact factor: 0.751

3.  Allergic reactions and risk of vulvodynia.

Authors:  Bernard L Harlow; Wei He; Ruby H N Nguyen
Journal:  Ann Epidemiol       Date:  2009-11       Impact factor: 3.797

4.  Vulvar vestibulitis syndrome.

Authors:  Carolyn Gardella
Journal:  Curr Infect Dis Rep       Date:  2006-11       Impact factor: 3.663

5.  Contact hypersensitivity to oxazolone provokes vulvar mechanical hyperalgesia in mice.

Authors:  Tijana Martinov; Rose Glenn-Finer; Sarah Burley; Elena Tonc; Evelyn Balsells; Alyssa Ashbaugh; Linnea Swanson; Randy S Daughters; Devavani Chatterjea
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

6.  A comparison of cognitive-behavioral couple therapy and lidocaine in the treatment of provoked vestibulodynia: study protocol for a randomized clinical trial.

Authors:  Serena Corsini-Munt; Sophie Bergeron; Natalie O Rosen; Marc Steben; Marie-Hélène Mayrand; Isabelle Delisle; Pierre McDuff; Leen Aerts; Marie Santerre-Baillargeon
Journal:  Trials       Date:  2014-12-23       Impact factor: 2.279

Review 7.  The Influence of Early Life Experience on Visceral Pain.

Authors:  Isabella M Fuentes; Julie A Christianson
Journal:  Front Syst Neurosci       Date:  2018-01-26

8.  New topical treatment of vulvodynia based on the pathogenetic role of cross talk between nociceptors, immunocompetent cells, and epithelial cells.

Authors:  J M Keppel Hesselink; D J Kopsky; N Sajben
Journal:  J Pain Res       Date:  2016-10-03       Impact factor: 3.133

Review 9.  Immunological and genetic characterization of women with vulvodynia.

Authors:  Stefan Gerber; Steven S Witkin; David Stucki
Journal:  J Med Life       Date:  2008 Oct-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.